GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (MEX:TSVT) » Definitions » COGS-to-Revenue

2seventy bio (MEX:TSVT) COGS-to-Revenue : 0.39 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio COGS-to-Revenue?

2seventy bio's Cost of Goods Sold for the three months ended in Jun. 2024 was MXN63.3 Mil. Its Revenue for the three months ended in Jun. 2024 was MXN164.3 Mil.

2seventy bio's COGS to Revenue for the three months ended in Jun. 2024 was 0.39.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. 2seventy bio's Gross Margin % for the three months ended in Jun. 2024 was 61.49%.


2seventy bio COGS-to-Revenue Historical Data

The historical data trend for 2seventy bio's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2seventy bio COGS-to-Revenue Chart

2seventy bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial 0.07 0.02 0.40 0.29 0.17

2seventy bio Quarterly Data
Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.41 0.29 0.36 0.39

2seventy bio COGS-to-Revenue Calculation

2seventy bio's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=287.17 / 1703.994
=0.17

2seventy bio's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=63.259 / 164.276
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


2seventy bio  (MEX:TSVT) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

2seventy bio's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 63.259 / 164.276
=61.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


2seventy bio COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of 2seventy bio's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


2seventy bio Business Description

Traded in Other Exchanges
Address
60 Binney Street, Cambridge, MA, USA, 02142
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.